These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 21894562)

  • 1. Detection of Slit2 promoter hypermethylation in tissue and serum samples from breast cancer patients.
    Kim GE; Lee KH; Choi YD; Lee JS; Lee JH; Nam JH; Choi C; Park MH; Yoon JH
    Virchows Arch; 2011 Oct; 459(4):383-90. PubMed ID: 21894562
    [TBL] [Abstract][Full Text] [Related]  

  • 2. GSTP1 promoter hypermethylation is an early event in breast carcinogenesis.
    Lee JS
    Virchows Arch; 2007 Jun; 450(6):637-42. PubMed ID: 17479284
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RUNX3 inactivation by frequent promoter hypermethylation and protein mislocalization constitute an early event in breast cancer progression.
    Subramaniam MM; Chan JY; Soong R; Ito K; Ito Y; Yeoh KG; Salto-Tellez M; Putti TC
    Breast Cancer Res Treat; 2009 Jan; 113(1):113-21. PubMed ID: 18256927
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Frequent promoter hypermethylation of BRCA2, CDH13, MSH6, PAX5, PAX6 and WT1 in ductal carcinoma in situ and invasive breast cancer.
    Moelans CB; Verschuur-Maes AH; van Diest PJ
    J Pathol; 2011 Oct; 225(2):222-31. PubMed ID: 21710692
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Promoter hypermethylation in ductal carcinoma in situ of the male breast.
    Vermeulen MA; van Deurzen CHM; Doebar SC; de Leng WWJ; Martens JWM; van Diest PJ; Moelans CB
    Endocr Relat Cancer; 2019 Jun; 26(6):575-584. PubMed ID: 30921768
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Promoter hypermethylation of SLIT2 is a risk factor and potential diagnostic biomarker for nasopharyngeal carcinoma.
    Li J; Zhou C; Wang G; Wang S; Ni S; Ye M; Zhang J
    Gene; 2018 Feb; 644():74-79. PubMed ID: 29107007
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protein expression and methylation of MGMT, a DNA repair gene and their correlation with clinicopathological parameters in invasive ductal carcinoma of the breast.
    Asiaf A; Ahmad ST; Malik AA; Aziz SA; Rasool Z; Masood A; Zargar MA
    Tumour Biol; 2015 Aug; 36(8):6485-96. PubMed ID: 25820821
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Frequent SLIT2 promoter methylation in the serum of patients with ovarian cancer.
    Dong R; Yu J; Pu H; Zhang Z; Xu X
    J Int Med Res; 2012; 40(2):681-6. PubMed ID: 22613430
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Silencing of tumor suppressor genes RASSF1A, SLIT2, and WIF1 by promoter hypermethylation in hereditary breast cancer.
    Alvarez C; Tapia T; Cornejo V; Fernandez W; Muñoz A; Camus M; Alvarez M; Devoto L; Carvallo P
    Mol Carcinog; 2013 Jun; 52(6):475-87. PubMed ID: 22315090
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Promoter CpG island hypermethylation during breast cancer progression.
    Park SY; Kwon HJ; Lee HE; Ryu HS; Kim SW; Kim JH; Kim IA; Jung N; Cho NY; Kang GH
    Virchows Arch; 2011 Jan; 458(1):73-84. PubMed ID: 21120523
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Profiling differential microRNA expression between in situ, infiltrative and lympho-vascular space invasive breast cancer: a pilot study.
    Soon PS; Provan PJ; Kim E; Pathmanathan N; Graham D; Clarke CL; Balleine RL
    Clin Exp Metastasis; 2018 Feb; 35(1-2):3-13. PubMed ID: 29214365
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Promoter hypermethylation of p16INK4A, p14ARF, CyclinD2 and Slit2 in serum and tumor DNA from breast cancer patients.
    Sharma G; Mirza S; Prasad CP; Srivastava A; Gupta SD; Ralhan R
    Life Sci; 2007 Apr; 80(20):1873-81. PubMed ID: 17383681
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low Expression and Promoter Hypermethylation of the Tumour Suppressor SLIT2, are Associated with Adverse Patient Outcomes in Diffuse Large B Cell Lymphoma.
    Mohamed G; Talima S; Li L; Wei W; Rudzki Z; Allam RM; Simmons W; Tao Q; Murray PG
    Pathol Oncol Res; 2019 Jul; 25(3):1223-1231. PubMed ID: 30739251
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection of RASSF1A aberrant promoter hypermethylation in sputum from chronic smokers and ductal carcinoma in situ from breast cancer patients.
    Honorio S; Agathanggelou A; Schuermann M; Pankow W; Viacava P; Maher ER; Latif F
    Oncogene; 2003 Jan; 22(1):147-50. PubMed ID: 12527916
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of Protein Expression and Methylation of DAPK1 with Clinicopathological Features in Invasive Ductal Carcinoma Patients from Kashmir.
    Asiaf A; Ahmad ST; Malik AA; Aziz SA; Zargar MA
    Asian Pac J Cancer Prev; 2019 Mar; 20(3):839-848. PubMed ID: 30912402
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of promoter hypermethylation detection in serum as a diagnostic tool for breast carcinoma in Korean women.
    Kim JH; Shin MH; Kweon SS; Park MH; Yoon JH; Lee JS; Choi C; Fackler MJ; Sukumar S
    Gynecol Oncol; 2010 Aug; 118(2):176-81. PubMed ID: 20466412
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Loss of expression and aberrant methylation of the CDH1 (E-cadherin) gene in breast cancer patients from Kashmir.
    Asiaf A; Ahmad ST; Aziz SA; Malik AA; Rasool Z; Masood A; Zargar MA
    Asian Pac J Cancer Prev; 2014; 15(15):6397-403. PubMed ID: 25124632
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical significance of promoter hypermethylation of DNA repair genes in tumor and serum DNA in invasive ductal breast carcinoma patients.
    Sharma G; Mirza S; Parshad R; Srivastava A; Gupta SD; Pandya P; Ralhan R
    Life Sci; 2010 Jul; 87(3-4):83-91. PubMed ID: 20470789
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PIK3CA mutations in ductal carcinoma in situ and adjacent invasive breast cancer.
    Agahozo MC; Sieuwerts AM; Doebar SC; Verhoef EI; Beaufort CM; Ruigrok-Ritstier K; de Weerd V; Sleddens HFBM; Dinjens WNM; Martens JWM; van Deurzen CHM
    Endocr Relat Cancer; 2019 May; 26(5):471-482. PubMed ID: 30844755
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical significance of Maspin promoter methylation and loss of its protein expression in invasive ductal breast carcinoma: correlation with VEGF-A and MTA1 expression.
    Sharma G; Mirza S; Parshad R; Srivastava A; Gupta SD; Pandya P; Ralhan R
    Tumour Biol; 2011 Feb; 32(1):23-32. PubMed ID: 20697987
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.